

# A New Immunostain Algorithm Classifies Diffuse Large Subtypes with High Accuracy

Clinical Cancer Research

15, 5494-5502

DOI: [10.1158/1078-0432.ccr-09-0113](https://doi.org/10.1158/1078-0432.ccr-09-0113)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Complexity Made Simple in Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 5291-5293.	3.2	6
2	New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009. <i>Journal of Hematopathology</i> , 2009, 2, 245-251.	0.2	1
3	Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. <i>Annals of Diagnostic Pathology</i> , 2009, 13, 413-427.	0.6	23
4	NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-34.	2.3	11
5	The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2010, 17, 333-358.	2.4	7
6	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
7	Genomic Analysis of Lymphoma: Potential for Clinical Application. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 353-360.	2.3	2
9	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 393-408.	157.7	143
10	Constitutive Canonical NF- $\kappa$ B Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma. <i>Cancer Cell</i> , 2010, 18, 580-589.	7.7	177
11	FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at <i>3p14.1</i> . <i>Histopathology</i> , 2010, 57, 73-80.	1.6	39
12	High immunohistochemical expression of pAKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2010, 149, 560-568.	1.2	71
13	Diffuse Large B-Cell Lymphoma in Chinese Patients. <i>American Journal of Clinical Pathology</i> , 2010, 133, 305-313.	0.4	34
14	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	0.6	200
15	Prognostic biomarkers in malignant lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 11-19.	0.6	21
16	Comparison of Choi and Hans' Algorithms by Immunohistochemistry and Quantitative Reverse Transcriptase-PCR Letter. <i>Clinical Cancer Research</i> , 2010, 16, 3805-3806.	3.2	1
17	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , 2010, 95, 1342-1349.	1.7	128
18	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
19	Biomarkers for Basal-like Breast Cancer. <i>Cancers</i> , 2010, 2, 1040-1065.	1.7	46

#	ARTICLE	IF	CITATIONS
20	Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 403-413.	1.1	11
21	Rearrangement of <i>MYC</i> Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab. <i>Journal of Clinical Oncology</i> , 2010, 28, 3360-3365.	0.8	511
22	New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 569-583.	1.0	2
23	Prognostication of diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2011, 52, 360-373.	0.6	28
24	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. <i>Leukemia and Lymphoma</i> , 2011, 52, 153-156.	0.6	6
25	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	0.6	316
26	Quick Reference Handbook for Surgical Pathologists. , 2011, , .		17
27	Biological Characterization of Nodal versus Extranodal Presentation of Diffuse Large B-Cell Lymphoma using Immunohistochemistry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 403-408.	0.2	9
28	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	0.6	1,681
29	Molecular pathogenesis of diffuse large B-cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 167-177.	1.0	72
30	Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy. <i>Journal of Korean Medical Science</i> , 2011, 26, 1556.	1.1	8
31	Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 288-292.	1.2	9
32	MYC and Aggressive B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2011, 18, 219-228.	2.4	129
33	Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?. <i>Proceedings of Singapore Healthcare</i> , 2011, 20, 48-54.	0.2	1
34	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040.	0.6	90
35	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011, 117, 4836-4843.	0.6	280
36	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 6342-6352.	0.6	93
37	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , 2011, 118, 5517-5527.	0.6	83

#	ARTICLE	IF	CITATIONS
38	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
39	Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. <i>International Journal of Oncology</i> , 2011, 39, 1413-20.	1.4	20
41	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
42	Early phase of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma of the elderly mimicking EBV-positive reactive follicular hyperplasia. <i>Histopathology</i> , 2011, 59, 571-575.	1.6	10
43	Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution. <i>Diagnostic Pathology</i> , 2011, 6, 77.	0.9	186
44	Germinal center B-cell-like diffuse large B-cell lymphoma of the duodenum is associated with t(14;18) translocation. <i>Pathology International</i> , 2011, 61, 742-748.	0.6	4
45	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
47	The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. <i>Journal of Pathology</i> , 2011, 223, 275-283.	2.1	21
48	Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer. <i>Stem Cells</i> , 2011, 29, 389-396.	1.4	151
49	EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. <i>American Journal of Hematology</i> , 2011, 86, 663-667.	2.0	65
50	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	2.0	125
51	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4079-4087.	0.8	248
52	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1495-1503.	0.6	20
53	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.4	71
54	Relapsed Diffuse Large B-Cell Lymphoma: Clinical Utility of Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4065-4066.	0.8	8
55	Genotypic and Phenotypic Differences between Nodal and Extranodal Diffuse Large B-Cell Lymphomas. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 918-931.	1.3	14
56	Pitfalls in lymphoma pathology: avoiding errors in diagnosis of lymphoid tissues. <i>Journal of Clinical Pathology</i> , 2011, 64, 466-476.	1.0	29
57	Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 506-514.	0.9	92

#	ARTICLE	IF	CITATIONS
58	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	0.8	426
59	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
60	B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 330-335.	0.9	6
61	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
62	The molecular biology of diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 369-379.	1.1	20
63	Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. <i>Leukemia and Lymphoma</i> , 2011, 52, 1681-1688.	0.6	18
64	Diffuse Large B-Cell Lymphoma Involving the Central Nervous System. <i>International Journal of Surgical Pathology</i> , 2011, 19, 44-50.	0.4	10
65	The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-10.	0.6	7
66	Use of interim [ <sup>18</sup> F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 263-269.	0.6	25
67	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
68	Molecular Characteristics of Diffuse Large B-cell Lymphoma, Not Otherwise Specified. , 2012, 17, 41-51.		1
69	Concordant and Discordant Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma: Are They Understudied Phenomena?. <i>Journal of Clinical Oncology</i> , 2012, 30, 336-336.	0.8	4
70	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2012, 25, 1439-1445.	2.9	5
71	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-κB activation. <i>Modern Pathology</i> , 2012, 25, 968-982.	2.9	172
72	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2012, 107, 491-500.	2.9	60
73	Expression of <i>MALT1</i> oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10534-10539.	3.3	73
74	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. <i>Oncologist</i> , 2012, 17, 1562-1573.	1.9	41
75	Molecular Profiling of Aggressive Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-9.	0.6	3

#	ARTICLE	IF	CITATIONS
76	The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 411-420.	1.0	102
77	Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions. <i>Cancer Control</i> , 2012, 19, 204-213.	0.7	99
78	Biological Prognostic Markers in Diffuse Large B-Cell Lymphoma. <i>Cancer Control</i> , 2012, 19, 214-226.	0.7	29
79	Primary Bone Marrow Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 296-304.	2.1	59
80	How I treat HIV-associated lymphoma. <i>Blood</i> , 2012, 119, 3245-3255.	0.6	140
81	A promising new biologic prognostic model in diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2161-2162.	0.6	1
83	Microarray Gene Expression Analysis of Fixed Archival Tissue Permits Molecular Classification and Identification of Potential Therapeutic Targets in Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 223-232.	1.2	24
84	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	3.3	301
85	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
86	Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions: Figure 1.. <i>Clinical Cancer Research</i> , 2012, 18, 4538-4548.	3.2	10
87	Diffuse Large B-Cell Lymphoma of the Orbit: Clinicopathologic, Immunohistochemical, and Prognostic Features of 20 Cases. <i>American Journal of Ophthalmology</i> , 2012, 154, 87-98.e1.	1.7	37
88	An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 313-321.	1.8	41
89	Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. <i>Diagnostic Pathology</i> , 2012, 7, 42.	0.9	333
90	Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2012, 181, 1879-1888.	1.9	31
91	Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 335-343.	0.6	12
92	Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. <i>Medical Oncology</i> , 2012, 29, 3352-3359.	1.2	13
93	CD68+ cell numbers and dendritic cell numbers and phenotype fail to predict the presence of a MYC rearrangement in aggressive B-cell lymphomas. <i>Journal of Hematopathology</i> , 2012, 5, 291-296.	0.2	0
94	Molecular Pathology of Malignant Lymphoma. <i>Surgical Pathology Clinics</i> , 2012, 5, 879-902.	0.7	0

#	ARTICLE	IF	CITATIONS
95	CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. <i>Annals of Hematology</i> , 2012, 91, 1897-1906.	0.8	18
96	Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 763-769.	0.6	15
97	VR09 Cell Line: An EBV-Positive Lymphoblastoid Cell Line with In Vivo Characteristics of Diffuse Large B Cell Lymphoma of Activated B-Cell Type. <i>PLoS ONE</i> , 2012, 7, e52811.	1.1	7
98	Germinal Center B-Cell-Like versus Non-Germinal Center B-Cell-Like as Important Prognostic Factor for Localized Nodal DLBCL. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2012, 52, 91-99.	0.3	9
99	Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients. <i>Scientific World Journal, The</i> , 2012, 2012, 1-7.	0.8	10
100	Treatment of Diffuse Large B Cell Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 369.	0.7	24
101	The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. <i>Neoplasma</i> , 2012, 60, 68-73.	0.7	16
102	Molecular genetic characterization of lymphoma: Application to cytology diagnosis. <i>Diagnostic Cytopathology</i> , 2012, 40, 542-555.	0.5	21
103	Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2012, 30, 143-149.	0.8	29
104	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 3006-3010.	2.3	28
105	Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. <i>Histopathology</i> , 2012, 61, 18-25.	1.6	22
106	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. <i>Histopathology</i> , 2012, 61, 33-46.	1.6	32
107	The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2012, 36, 413-417.	0.4	45
108	The Hans classifier does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. <i>Leukemia Research</i> , 2012, 36, 544-545.	0.4	11
109	Progression of double-hit lymphoma in the midst of R-hyper CVAD. <i>American Journal of Hematology</i> , 2013, 88, 87-88.	2.0	3
110	Diffuse large B-cell lymphoma of the ocular adnexal region: A nation-based study. <i>Acta Ophthalmologica</i> , 2013, 91, 163-169.	0.6	29
111	Developments in the immunophenotypic analysis of haematological malignancies. <i>Blood Reviews</i> , 2013, 27, 193-207.	2.8	11
112	Cancer Genomics. , 2013, , .		4

#	ARTICLE	IF	CITATIONS
113	I. Pathological and clinical diversity in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2013, 31, 23-25.	0.8	3
114	The Impact of MYC Rearrangements and "Double Hit" Abnormalities in Diffuse Large B-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 243-252.	1.2	30
115	Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. <i>Annals of Diagnostic Pathology</i> , 2013, 17, 250-255.	0.6	15
116	Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8). <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 113-129.	1.0	8
117	Burkitt's Lymphoma. , 2013, , .		2
118	Nuclear factor- $\kappa$ B activation in primary lymphoma of bone. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 349-354.	1.4	8
119	Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 226-235.	1.2	7
120	Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). <i>International Journal of Hematology</i> , 2013, 97, 465-471.	0.7	14
121	Large Cell Lymphoma: Correlation of HIV Status and Prognosis with Differentiation Profiles Assessed by Immunophenotyping. <i>Pathology and Oncology Research</i> , 2013, 19, 695-705.	0.9	14
122	Correlation Between Immunophenotype Classification and Clinicopathological Features in Chinese Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. <i>Pathology and Oncology Research</i> , 2013, 19, 317-322.	0.9	3
123	Primary adrenal lymphoma: a systematic review. <i>Annals of Hematology</i> , 2013, 92, 1583-1593.	0.8	156
124	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	0.8	113
125	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. <i>Histopathology</i> , 2013, 63, 788-801.	1.6	25
126	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. <i>Acta Ophthalmologica</i> , 2013, 91, 1-27.	0.6	37
127	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e548-e561.	5.1	21
128	Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. <i>Cancer Genetics</i> , 2013, 206, 257-265.	0.2	21
129	Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum. <i>Leukemia and Lymphoma</i> , 2013, 54, 967-972.	0.6	11
131	Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. <i>Leukemia and Lymphoma</i> , 2013, 54, 1934-1941.	0.6	18

#	ARTICLE	IF	CITATIONS
132	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	2.0	323
133	Tissue microarray in a subset of South African patients with DLBCL. <i>Transfusion and Apheresis Science</i> , 2013, 49, 120-132.	0.5	1
134	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
135	Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Academic Radiology</i> , 2013, 20, 1122-1129.	1.3	9
136	Lymphomas of the Gastrointestinal Tract. <i>Surgical Pathology Clinics</i> , 2013, 6, 405-424.	0.7	2
137	Primary dural lymphoma: A novel concept of heterogeneous disease. <i>Pathology International</i> , 2013, 63, 68-72.	0.6	16
138	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
139	Pathology of Non-Hodgkinâ€™s and Hodgkinâ€™s Lymphomas. , 2013, , 867-918.		0
140	Diffuse Large B-Cell Lymphoma. , 2013, , 151-173.		1
141	MicroRNAs in hematological malignancies. <i>Blood Reviews</i> , 2013, 27, 143-154.	2.8	53
142	<sc>B</sc>â€™cell lymphoma, unclassifiable, with features intermediate between diffuse large <sc>B</sc>â€™cell lymphoma and burkitt lymphoma: study of 39 cases. <i>British Journal of Haematology</i> , 2013, 162, 40-49.	1.2	73
143	Molecular pathology of lymphoma. <i>Eye</i> , 2013, 27, 180-189.	1.1	51
144	Differences in the cytogenetic alteration profiles of diffuse large B-cell lymphoma among Chinese and American patients. <i>Cancer Genetics</i> , 2013, 206, 183-190.	0.2	6
145	Antibody-Drug Conjugates and Immunotoxins. , 2013, , .		5
147	Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 43-57.	1.1	18
148	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. <i>Annals of Oncology</i> , 2013, 24, 1385-1392.	0.6	99
149	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	0.6	50
150	Vitreoretinal Presentation of Secondary Large B-Cell Lymphoma in Patients With Systemic Lymphoma. <i>JAMA Ophthalmology</i> , 2013, 131, 1151.	1.4	66

#	ARTICLE	IF	CITATIONS
151	Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL. <i>Cancer Research</i> , 2013, 73, 5029-5039.	0.4	118
152	Lymphoid Proliferations Associated With Human Immunodeficiency Virus Infection. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 360-370.	1.2	51
153	30 Years of Lymph Node Pathology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 103-109.	0.6	3
154	A Reappraisal of the Diagnostic and Therapeutic Management of Uncommon Histologies of Primary Ocular Adnexal Lymphoma. <i>Oncologist</i> , 2013, 18, 876-884.	1.9	36
155	Aggressive B-cell lymphomas: how many categories do we need?. <i>Modern Pathology</i> , 2013, 26, S42-S56.	2.9	47
156	Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2013, 19, 6686-6695.	3.2	115
157	MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2149-2154.	0.6	16
158	Receptor tyrosine kinases <sc>MET</sc> and <sc>RON</sc> as prognostic factors in diffuse large B-cell lymphoma patients receiving Râ€<sc>CHOP</sc>. <i>Cancer Science</i> , 2013, 104, 1245-1251.	1.7	12
159	Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy. <i>European Journal of Haematology</i> , 2013, 91, 29-36.	1.1	3
160	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. <i>Blood Research</i> , 2013, 48, 266.	0.5	16
161	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 0, , 17.	0.4	1
162	MicroRNA Profiling of Primary Cutaneous Large B-Cell Lymphomas. <i>PLoS ONE</i> , 2013, 8, e82471.	1.1	20
163	Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e98169.	1.1	31
164	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2014, 9, e111840.	1.1	63
165	Diffuse large B-cell lymphoma: The history, current view and new perspectives. <i>Neoplasma</i> , 2014, 62, 491-504.	0.7	10
166	Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 117-127.	0.3	4
167	An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2014, 55, 2466-2476.	0.6	94
168	Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas. <i>BMC Cancer</i> , 2014, 14, 911.	1.1	24

#	ARTICLE	IF	CITATIONS
169	Molecular Genetics of Diffuse Large B-Cell Lymphoma. , 2014, , 1677-1686.		0
170	Implementing a Multi-analyte Immunohistochemistry Panel into a Drug Development Program. Methods in Pharmacology and Toxicology, 2014, , 345-358.	0.1	0
171	Analysis of clinical characteristics of 516 patients with non-Hodgkin's lymphoma in Shanghai area. Hematology, 2014, 19, 99-106.	0.7	3
172	Gene translocations in testicular lymphomas. Leukemia and Lymphoma, 2014, 55, 1410-1412.	0.6	18
173	NF $\kappa$ B expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Modern Pathology, 2014, 27, 1331-1337.	2.9	27
174	Focal adhesion protein expression in human diffuse large B-cell lymphoma. Histopathology, 2014, 65, 119-131.	1.6	9
175	p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression. American Journal of Clinical Pathology, 2014, 141, 593-604.	0.4	46
176	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia, 2014, 28, 362-372.	3.3	27
177	High Concordance of Gene Expression Profilingâ€“correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise Specified. American Journal of Surgical Pathology, 2014, 38, 1046-1057.	2.1	33
178	CNS Lymphoma. Journal of Neuropathology and Experimental Neurology, 2014, 73, 478-494.	0.9	92
179	Clinical Significance of MYC Expression and/or â€œHigh-gradeâ€•Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 494-501.	2.1	43
180	Digital Pathology for the Validation of Tissue Microarrays in Peripheral T-cell Lymphomas. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 577-584.	0.6	5
181	Genetic and Immunohistochemical Characterization of Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma. Acta Haematologica, 2014, 131, 1-10.	0.7	8
182	c-Myc Immunohistochemistry in Diffuse Large B Cell Lymphoma. , 2014, 19, 234-238.		2
183	Genetics of Diffuse Large B-Cell Lymphoma. Cancer Journal (Sudbury, Mass ), 2014, 20, 43-47.	1.0	4
184	Decision Tools for Radiation Oncology. Medical Radiology, 2014, , .	0.0	2
185	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. Annals of Hematology, 2014, 93, 437-447.	0.8	19
186	How we treat Richter syndrome. Blood, 2014, 123, 1647-1657.	0.6	145

#	ARTICLE	IF	CITATIONS
187	miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. <i>Blood</i> , 2014, 124, 84-95.	0.6	129
188	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. <i>Annals of Oncology</i> , 2014, 25, 2124-2133.	0.6	141
189	A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. <i>Modern Pathology</i> , 2014, 27, 524-534.	2.9	61
190	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. <i>Experimental Hematology</i> , 2014, 42, 927-938.	0.2	15
191	<sc>CD</sc>30 expression in <i>de novo</i> diffuse large B-cell lymphoma: a population-based study from British Columbia. <i>British Journal of Haematology</i> , 2014, 167, 608-617.	1.2	84
192	MicroRNAs: Key Regulators of Oncogenesis. , 2014, , .		14
193	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	3.2	117
194	Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3534-43.	3.3	62
195	Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 294-299.	1.2	38
196	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
197	Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype. <i>Clinical Cancer Research</i> , 2014, 20, 5182-5193.	3.2	34
198	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. <i>Annals of Hematology</i> , 2014, 93, 1867-1877.	0.8	16
199	<sc>MYC</sc> and <sc>BCL</sc>2 protein expression predicts survival in patients with diffuse large <sc>B</sc>-cell lymphoma treated with rituximab. <i>British Journal of Haematology</i> , 2014, 165, 382-391.	1.2	157
200	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	2.0	32
201	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. <i>Annals of Hematology</i> , 2014, 93, 1263-1277.	0.8	48
202	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
203	CD79B and MYD88 mutations in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 556-564.	1.1	43
204	Primary lymphoma of the central nervous system—a diagnostic challenge. <i>Hematological Oncology</i> , 2014, 32, 57-67.	0.8	52

#	ARTICLE	IF	CITATIONS
205	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
206	Pathology Consultation on Intermediate-to-Large B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2014, 141, 305-317.	0.4	7
207	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	1.7	2
208	High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab. <i>International Journal of Hematology</i> , 2015, 102, 662-669.	0.7	20
209	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
210	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. <i>Blood</i> , 2015, 126, 1893-1901.	0.6	117
211	Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. <i>Scientific Reports</i> , 2015, 5, 12168.	1.6	84
212	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1501-1508.	2.3	28
213	P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. <i>BMC Cancer</i> , 2015, 15, 722.	1.1	28
214	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. <i>European Journal of Haematology</i> , 2015, 95, 442-448.	1.1	30
215	Aggressive B-Cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2015, 22, 168-180.	2.4	9
216	Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e458-e466.	1.8	47
217	MicroRNAs as B-cell lymphoma biomarkers. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015, , 25.	1.2	2
218	Immunohistochemical subtypes of diffuse large B-cell lymphoma in the head and neck region. <i>Genetics and Molecular Research</i> , 2015, 14, 3889-3896.	0.3	7
219	MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. <i>Current Genomics</i> , 2015, 16, 349-358.	0.7	24
220	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 1016-1021.	0.6	46
221	Ocular Adnexal Diffuse Large B-cell Lymphoma. <i>JAMA Ophthalmology</i> , 2015, 133, 165.	1.4	60
222	QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 402-411.	1.2	11

#	ARTICLE	IF	CITATIONS
223	Multiplex sequencing for <i>EZH2</i> , <i>CD79B</i> , and <i>MYD88</i> mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for <i>MYC</i> rearrangement and <i>IGH/BCL2</i> translocation. <i>Cancer Cytopathology</i> , 2015, 123, 413-420.	1.4	15
224	Update in large cell lymphoma: understanding the pathology report. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 605-617.	0.9	3
225	CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast. <i>Pathobiology</i> , 2015, 82, 259-263.	1.9	6
226	Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. <i>Journal of Geriatric Oncology</i> , 2015, 6, 141-152.	0.5	61
227	Genetic lesions in diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2015, 26, 1069-1080.	0.6	65
228	The Histological Classification of Diffuse Large B-cell Lymphomas. <i>Seminars in Hematology</i> , 2015, 52, 57-66.	1.8	67
229	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. <i>Leukemia</i> , 2015, 29, 1564-1570.	3.3	54
230	When and how to test for C-MYC in aggressive B cell lymphomas. <i>Journal of Hematopathology</i> , 2015, 8, 13-20.	0.2	2
231	CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. <i>Human Pathology</i> , 2015, 46, 593-599.	1.1	32
232	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
233	Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1094-1107.	1.2	33
234	Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 345-355.	1.4	17
235	Gene Expression Profiling in Non-Hodgkin Lymphomas. <i>Cancer Treatment and Research</i> , 2015, 165, 97-123.	0.2	3
236	Clinicopathological correlates of primary central nervous system lymphoma: Experience from a tertiary care center in South India. <i>Neurology India</i> , 2015, 63, 77.	0.2	13
238	Clinicopathological implications of nuclear factor $\kappa$ B signal pathway activation in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2015, 46, 524-531.	1.1	9
239	Recent advances in intestinal lymphomas. <i>Histopathology</i> , 2015, 66, 112-136.	1.6	60
240	Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. <i>Cancer Treatment and Research</i> , 2015, 165, 27-50.	0.2	10
241	Molecular Pathogenesis of B Cell Lymphomas. , 2015, , 399-416.		0

#	ARTICLE	IF	CITATIONS
242	Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1379-1388.	0.8	94
243	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	1.8	16
244	An Oncogenic Role for Alternative NF- $\kappa$ B Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. <i>Cell Reports</i> , 2015, 11, 715-726.	2.9	66
245	Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System. <i>Clinical Cancer Research</i> , 2015, 21, 2367-2378.	3.2	65
246	Differential Expression of miR-155 and miR-21 in Tumor and Stroma Cells in Diffuse Large B-Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 188-195.	0.6	10
247	Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a $\kappa$ String. <i>Clinical Cancer Research</i> , 2015, 21, 2204-2206.	3.2	1
248	Diffuse Large B-cell Lymphoma of Germinal Center and Nongerminal Center Phenotypes Presenting Concurrently at the Same Anatomic Site. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 78-80.	0.6	1
249	Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. <i>Histopathology</i> , 2015, 67, 625-635.	1.6	25
250	The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. <i>Current Topics in Microbiology and Immunology</i> , 2015, 390, 315-337.	0.7	23
251	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v116-v125.	0.6	621
252	Diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Diagnostic Histopathology</i> , 2015, 21, 391-399.	0.2	0
253	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	1.1	8
254	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Experimental and Molecular Pathology</i> , 2015, 99, 537-545.	0.9	13
255	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees. <i>Journal of Clinical Oncology</i> , 2015, 33, 2835-2836.	0.8	25
256	Lymphoma and Lymphoproliferative Disorders. , 2015, , 619-644.		0
257	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	1.7	87
258	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , 2015, 169, 188-198.	1.2	49
259	Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR. <i>Laboratory Investigation</i> , 2015, 95, 113-120.	1.7	17

#	ARTICLE	IF	CITATIONS
260	Clinical Prognostic Biomarkers in Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2015, 139, 602-607.	1.2	15
261	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leukemia and Lymphoma, 2015, 56, 2141-2145.	0.6	77
262	Genetic analysis of B-cell lymphomas associated with hemophagocytic lymphohistiocytosis. Blood Advances, 2016, 1, 205-207.	2.5	5
263	Oct2, BCL6, IRF8, OCAB and PU.1 in the Assessment of Prognosis in Diffuse Large B cell Lymphoma Patients. Journal of Molecular Biomarkers & Diagnosis, 2016, 07, .	0.4	1
264	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	0.8	93
265	Hematopoietic System. , 2016, , 102-268.e1.		60
266	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	0.8	26
267	miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International, 2016, 2016, 1-14.	0.9	56
268	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, 324-334.	2.1	57
269	Clinical approach to diffuse large B cell lymphoma. Blood Reviews, 2016, 30, 477-491.	2.8	26
270	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology and Laboratory Medicine, 2016, 140, 1225-1227.	1.2	6
271	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. Cancer Cytopathology, 2016, 124, 135-143.	1.4	30
272	Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology, 2016, 29, 1118-1142.	2.9	36
273	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology, 2016, 68, 1079-1089.	1.6	135
274	The distinct clinical features and prognosis of the CD10+MUM1+ and CD10 <sup>+</sup> Bcl6 <sup>+</sup> MUM1 <sup>+</sup> diffuse large B-cell lymphoma. Scientific Reports, 2016, 6, 20465.	1.6	22
275	Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Science, 2016, 107, 1572-1580.	1.7	5
276	Lymphoma: turning biology into cures. Clinical Medicine, 2016, 16, s125-s129.	0.8	5
277	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	5.8	42

#	ARTICLE	IF	CITATIONS
278	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. <i>Nuclear Medicine Communications</i> , 2016, 37, 1095-1101.	0.5	15
279	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. <i>Advances in Anatomic Pathology</i> , 2016, 23, 202-243.	2.4	15
280	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106
281	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. <i>Surgical Pathology Clinics</i> , 2016, 9, 41-54.	0.7	5
282	FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. <i>Leukemia</i> , 2016, 30, 605-616.	3.3	61
283	Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. <i>Blood</i> , 2016, 127, 181-186.	0.6	21
284	The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. <i>Blood</i> , 2016, 127, 1438-1448.	0.6	59
286	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33
287	Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles. <i>Cancer Medicine</i> , 2016, 5, 837-852.	1.3	27
288	Guidelines for the management of diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 43-56.	1.2	125
289	MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2016, 107, 853-861.	1.7	35
290	Molecular Classification of Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1163-1177.	0.9	22
291	Detection of the value of consecutive serum total light chain (sTLC) in patients diagnosed with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1999-2007.	0.8	1
292	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1093-1102.	1.5	3
293	Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell of origin, and frequency of MYD88 L265P. <i>Pathology International</i> , 2016, 66, 444-452.	0.6	23
294	Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 961-967.	0.8	8
295	Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin's Lymphoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 556-564.	1.3	11
296	Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. <i>Clinica Chimica Acta</i> , 2016, 463, 47-52.	0.5	7

#	ARTICLE	IF	CITATIONS
297	Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 679-683.	0.2	8
298	CD10 expression in the neuroendocrine carcinoma component of endometrial mixed carcinoma: association with long survival. <i>Diagnostic Pathology</i> , 2016, 11, 16.	0.9	3
299	Canine lymphoma: a review. <i>Veterinary Quarterly</i> , 2016, 36, 76-104.	3.0	123
300	Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists. <i>Pathology</i> , 2016, 48, 5-16.	0.3	8
301	Richter Syndrome in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 43-51.	1.2	15
302	Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients – a pilot study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1814-1822.	0.6	16
303	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1138-1149.	3.2	82
304	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 253-262.	0.8	19
305	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 175-189.	1.0	7
306	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	0.6	7
307	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1640-1648.	0.6	12
308	Primary testicular diffuse large B-cell lymphoma: morphological and immunophenotypical study with characterization of the T-cell component of the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2016, 57, 477-479.	0.6	5
309	Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 341-354.	1.2	6
310	Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
311	Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC , BCL-2 , and BCL-6. <i>Pathology Research and Practice</i> , 2017, 213, 659-665.	1.0	9
312	Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, e553-e553.	2.8	9
313	The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 557-566.	1.5	18
314	Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001719.	0.5	22

#	ARTICLE	IF	CITATIONS
315	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1322-1332.	2.1	23
316	An update for Richter syndrome – new directions and developments. <i>British Journal of Haematology</i> , 2017, 178, 508-520.	1.2	28
317	2016 WHO Classification update – What's new in lymphoid neoplasms. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 14-22.	0.7	16
318	Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1236-1246.	1.2	20
319	Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. <i>Blood</i> , 2017, 129, 280-288.	0.6	125
320	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017, 129, 759-770.	0.6	69
321	Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 925-934.	0.6	8
322	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	1.0	14
323	Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. <i>British Journal of Haematology</i> , 2017, 178, 871-887.	1.2	41
324	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. <i>Annals of Hematology</i> , 2017, 96, 1867-1871.	0.8	29
325	Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e91-e97.	0.2	7
326	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 783-796.	0.2	29
327	Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 697-705.	1.0	26
328	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<sc>DLBCL</sc>) reveals gain at 1q31 and <sc>RGS</sc> 1 encoding protein; high <sc>RGS</sc> 1 immunohistochemical expression associates with poor overall survival in <sc>DLBCL</sc> not otherwise specified (<sc>NOS</sc>). <i>Histopathology</i> , 2017, 70, 595-621.	1.6	41
329	BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1269-1279.	0.8	18
330	Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1130-1134.	0.6	11
331	Epidemiology of Hematologic Malignancies. , 2017, , 543-569.		9
332	The significance of FOXP1 in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1037-1051.	0.6	50

#	ARTICLE	IF	CITATIONS
333	Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2017, 31, 1-11.	1.2	9
334	Aggressive lymphoma 2016: revision of the WHO classification. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 248-254.	0.3	32
335	KLHL6 Is Preferentially Expressed in Germinal Centerâ€Derived B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 465-476.	0.4	7
336	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 284-294.	0.9	22
337	Health Disparities and the Global Landscape of Lymphoma Care Today. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 526-534.	1.8	16
338	Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 54-63.	0.3	20
339	Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2515-2526.	0.8	179
340	Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Nonâ€Germinal Center B-Cellâ€Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3538-3546.	0.8	151
341	Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. <i>Oncotarget</i> , 2017, 8, 22014-22022.	0.8	40
342	Richter transformation driven by Epsteinâ€Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	2.1	24
343	Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 677-679.	3.3	2
344	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 2304-2311.	3.2	11
345	Pathology of Non-Hodgkin and Hodgkin Lymphomas. , 2018, , 773-826.		0
346	CAR T cell therapy for B-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 135-146.	0.7	39
347	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies. <i>Blood Reviews</i> , 2018, 32, 249-255.	2.8	29
348	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. <i>Annals of Oncology</i> , 2018, 29, 707-714.	0.6	46
349	Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphomaâ€a feasibility study using full slide staining. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 341-349.	1.4	5
350	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. <i>Blood Reviews</i> , 2018, 32, 400-415.	2.8	49

#	ARTICLE	IF	CITATIONS
351	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
352	Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 215-221.	1.4	14
353	Intravascular large B-cell lymphoma presenting clinically as rapidly progressive dementia. <i>Irish Journal of Medical Science</i> , 2018, 187, 319-322.	0.8	10
354	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	0.6	28
355	Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. <i>Annals of Hematology</i> , 2018, 97, 1-15.	0.8	35
356	Diffuse large B-cell lymphoma. <i>Pathology</i> , 2018, 50, 74-87.	0.3	395
357	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 288-296.	1.7	15
358	Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 254-262.	0.6	8
359	Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. <i>Journal of Clinical Pathology</i> , 2018, 71, 215-220.	1.0	13
360	Conjunctival lymphomas in Japanese monozygotic twins: A case report. <i>Oncology Letters</i> , 2019, 17, 1313-1319.	0.8	1
361	Diffuse Aggressive B-Cell Lymphomas. , 2018, , 271-305.e5.		0
362	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 32383-32399.	0.8	9
363	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
364	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	0.6	45
365	De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas?. <i>Chonnam Medical Journal</i> , 2018, 54, 80.	0.5	2
366	Recent Advances in Diffuse Large B Cell Lymphoma. , 2018, , .		2
367	An update on high grade B-cell lymphoma. <i>Diagnostic Histopathology</i> , 2018, 24, 237-245.	0.2	1
368	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	0.8	13

#	ARTICLE	IF	CITATIONS
370	Coexpression of CD 5 and CD 43 predicts worse prognosis in diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2018, 7, 4284-4295.	1.3	13
371	Diagnosis of Lymphoid Lesions in Limited Samples. <i>American Journal of Clinical Pathology</i> , 2018, 150, 471-484.	0.4	14
372	Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. <i>Journal of Translational Medicine</i> , 2018, 16, 162.	1.8	17
373	Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 187-198.	0.7	2
374	Gammaherpesvirus infection and malignant disease in rhesus macaques experimentally infected with SIV or SHIV. <i>PLoS Pathogens</i> , 2018, 14, e1007130.	2.1	10
375	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22
376	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018, 103, 1351-1358.	1.7	49
377	An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. <i>PLoS Pathogens</i> , 2018, 14, e1007221.	2.1	22
378	Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification. <i>Polish Journal of Pathology</i> , 2018, 69, 1-19.	0.1	7
379	The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. <i>Journal of Molecular Biology</i> , 2018, 430, 2875-2899.	2.0	72
380	Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2018, 15, 6903-6912.	0.8	14
381	Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: An indicator of good prognosis. <i>Auris Nasus Larynx</i> , 2019, 46, 114-121.	0.5	18
382	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e57.	0.6	3
383	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 207-218.	1.2	17
384	Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. <i>Expert Review of Hematology</i> , 2019, 12, 1095-1105.	1.0	5
385	A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas. <i>PLoS ONE</i> , 2019, 14, e0223260.	1.1	4
386	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	1.0	18
387	Reproducing the molecular subclassification of peripheral T-cell lymphoma – NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	0.6	120

#	ARTICLE	IF	CITATIONS
388	Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 572-580.	0.6	17
389	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma. <i>Diagnostic Pathology</i> , 2019, 14, 45.	0.9	5
390	Lymphoid neoplasms of the sinonasal tract and their differential diagnoses. <i>Diagnostic Histopathology</i> , 2019, 25, 274-280.	0.2	0
391	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , 2019, 6, e000324.	1.1	16
392	High-grade B-cell lymphoma: how to diagnose and treat. <i>Expert Review of Hematology</i> , 2019, 12, 497-506.	1.0	15
394	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. <i>Journal of Translational Medicine</i> , 2019, 17, 198.	1.8	8
395	Primär kutanes diffusgroßzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 275-286.	0.4	1
396	Treatment outcome and prognostic factors in PCNSL. <i>Diagnostic Pathology</i> , 2019, 14, 56.	0.9	24
397	Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	3
398	Immunostains: Hematopoietic System. , 2019, , 49-58.		0
399	The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. <i>Molecular Biology Reports</i> , 2019, 46, 4063-4076.	1.0	7
400	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
401	Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis. <i>American Journal of Pathology</i> , 2019, 189, 1462-1472.	1.9	14
402	Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 275-285.	0.4	15
403	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. <i>Scientific Reports</i> , 2019, 9, 2554.	1.6	18
404	Spontaneous remission in diffuse large cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 28.	0.4	15
405	Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis. <i>Analytical Cellular Pathology</i> , 2019, 2019, 1-9.	0.7	50
406	nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 644-648.	0.6	9

#	ARTICLE	IF	CITATIONS
407	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
408	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. <i>Blood Advances</i> , 2019, 3, 3953-3961.	2.5	22
409	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 699-707.	0.7	13
410	Human Immunodeficiency Virus-Associated Lymphoproliferative Disorders. <i>Surgical Pathology Clinics</i> , 2019, 12, 771-782.	0.7	3
411	A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF- $\kappa$ B-double-targeting to molecularly assess therapy response. <i>International Journal of Hematologic Oncology</i> , 2019, 8, IJH20.	0.7	7
412	Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. <i>Leukemia Research</i> , 2019, 76, 107-111.	0.4	6
413	Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 57-67.	2.0	27
414	Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation. <i>Human Pathology</i> , 2020, 96, 67-78.	1.1	12
415	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020, 188, 413-423.	1.2	5
416	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 620-629.	1.1	12
417	The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1133-1139.	0.6	6
418	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 176-183.	0.9	33
419	HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA. <i>Retina</i> , 2020, 40, 391-398.	1.0	4
420	Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 207-213.	1.1	5
421	Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 232-240.	2.1	4
422	Clinical Features of 50 Patients With Primary Adrenal Lymphoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 595.	1.5	18
423	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. <i>Cancers</i> , 2020, 12, 2913.	1.7	24
424	Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma. <i>Diagnostics</i> , 2020, 10, 1002.	1.3	2

#	ARTICLE	IF	CITATIONS
425	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 123.	2.8	47
426	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
428	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2020, 126, 3493-3503.	2.0	15
429	Molecular Diagnostics of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 186-194.	1.0	3
430	Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 1267-1281.	7.7	40
431	Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi. <i>Modern Pathology</i> , 2020, 33, 1482-1491.	2.9	6
432	<i>MYC</i> rearrangement and <i>MYC/BCL2</i> double expression but not cell-of-origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	1.1	15
433	Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?. <i>Cancers</i> , 2020, 12, 185.	1.7	22
434	Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies. <i>Translational Medicine Communications</i> , 2020, 5, .	0.5	11
435	Cytogenetic complexity and heterogeneity in intravascular lymphoma. <i>Journal of Clinical Pathology</i> , 2021, 74, 244-250.	1.0	6
436	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 284-294.	1.1	12
437	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. <i>American Journal of Clinical Pathology</i> , 2021, 155, 748-754.	0.4	9
438	Increased <i>MYC</i> expression without <i>MYC</i> gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 120-125.	0.3	1
439	Immunohistochemical subtypes of non-hodgkin lymphomas with special emphasis on diffuse large B-cell lymphoma: An epidemiological study in a tertiary care center of Eastern India. <i>Biomedical and Biotechnology Research Journal</i> , 2021, 5, 149.	0.3	2
440	Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110139.	1.1	11
441	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198957.	1.1	9
442	Indolent and Aggressive B-Cell Lymphoma. , 2021, , 217-250.		0
443	Impact of Genetic Polymorphism of Myeloid Differentiation Primary Response Gene 88, Enhancer of Zeste Homolog 2, and B-cell Lymphoma 2 like 11 in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin. <i>Open Access Macedonian Journal of Medical Sciences</i> . 2021, 9, 98-105.	0.1	0

#	ARTICLE	IF	CITATIONS
444	Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021, 10, 675.	1.8	10
445	Genomic characterisation of diffuse large B-cell lymphoma. <i>Pathology</i> , 2021, 53, 367-376.	0.3	9
446	Precision Medicine in DLBCL: Are We There Yet?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1314-1316.	0.8	5
447	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	0.6	3
448	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638154.	1.3	4
449	MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab090.	0.4	3
450	Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective. <i>HemaSphere</i> , 2021, 5, e621.	1.2	0
451	Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features. <i>Cancers</i> , 2021, 13, 4049.	1.7	11
452	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 49-55.	0.6	2
453	Lymph Nodes. , 2022, , 763-813.		0
454	Pathology of Lung Cancer. , 2022, , 765-784.		0
455	Predictive Biomarkers for Antibody-Drug Conjugates. , 2013, , 77-90.		2
456	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. <i>Methods in Molecular Biology</i> , 2019, , 41-73.	0.4	2
457	Diffuse Large B-Cell Lymphomas in Older Adults. , 2020, , 583-612.		1
458	Diffuse Aggressive B-Cell Lymphomas. , 2012, , 261-292.		1
459	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
460	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 731-740.	0.6	7
461	Recent advances in upper gastrointestinal lymphomas: molecular updates and diagnostic implications. <i>Histopathology</i> , 2021, 78, 187-214.	1.6	11

#	ARTICLE	IF	CITATIONS
462	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-9.	0.9	44
463	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-409.	0.9	48
464	Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. F1000Research, 2018, 7, 1966.	0.8	2
465	A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma. PLoS ONE, 2013, 8, e55895.	1.1	64
466	Clinicopathologic Analysis of Localized Nasal/Paranasal Diffuse Large B-Cell Lymphoma. PLoS ONE, 2013, 8, e57677.	1.1	10
468	PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas. Oncotarget, 2016, 7, 59158-59172.	0.8	12
469	GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. Oncotarget, 2016, 7, 65284-65294.	0.8	34
470	Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. Oncotarget, 2017, 8, 16243-16258.	0.8	8
471	Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients. Oncotarget, 2017, 8, 9708-9716.	0.8	9
472	Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 19556-19565.	0.8	12
473	mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. Oncotarget, 2017, 8, 50949-50957.	0.8	31
474	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 15035-15049.	0.8	94
475	SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Oncotarget, 2013, 4, 35-47.	0.8	44
476	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Oncotarget, 2016, 7, 52940-52956.	0.8	16
477	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1229-1236.	0.5	9
478	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India. , 2020, 11, 424.		8
479	Gastrointestinal lymphoproliferative lesions: a practical diagnostic approach. Pathologica, 2020, 112, 227-247.	1.3	7
480	Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival. Indian Journal of Pathology and Microbiology, 2015, 58, 453.	0.1	10

#	ARTICLE	IF	CITATIONS
481	Machine Learning Provides an Accurate Classification of Diffuse Large B-Cell Lymphoma from Immunohistochemical Data. <i>Journal of Pathology Informatics</i> , 2018, 9, 21.	0.8	7
482	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 224-241.	0.4	12
483	Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. <i>Swiss Medical Weekly</i> , 2013, 143, w13748.	0.8	10
484	The Immunohistochemistry Laboratory: Looking at Molecules and Preparing for Tomorrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1659-1665.	1.2	27
485	Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1341-1347.	0.5	6
486	Precision diagnostics in lymphomas – Recent developments and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 170-183.	4.3	13
487	A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. <i>Blood Advances</i> , 2022, 6, 2388-2402.	2.5	8
488	Molecular Pathogenesis of Aggressive B-cell Lymphomas. <i>Principles and Practice</i> , 2012, , 55-70.	0.3	0
489	Non-Hodgkin's Lymphomas. , 2012, , 115-157.		0
490	Primary Extranodal B-cell Lymphoma. <i>International Journal of Experimental Dental Science</i> , 2012, 1, 30-33.	0.1	1
491	Where Do We Stand in the Genomics of Lymphomas?. , 2013, , 495-541.		0
492	Genomic Analysis of B-Cell Lymphomas. , 2013, , 35-51.		0
493	Diffuse Large B-Cell Lymphoma. , 2013, , 177-202.		0
494	MicroRNAs and Blood Cancers. , 2014, , 129-153.		0
495	Diffuse Large B-Cell Lymphoma. , 2016, , 230-233.		23
496	Expression IRF/MUM1 > 25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2016, 70, 342.	0.4	2
498	Lymphoid and Hematopoietic Tumors of the Breast. , 2016, , 725-741.		0
499	Thyroid Lymphoma. , 2016, , 913-920.		0

#	ARTICLE	IF	CITATIONS
500	Cutaneous Richter Syndrome mimicking a lower limb cellulitis infection - a case report and review of the literature. <i>Dermatology Online Journal</i> , 2016, 22, .	0.2	1
501	Case report. A rare case of triple-hit diffuse large B-cell lymphoma of the parotid gland in a patient with Sjogren's syndrome. <i>Romanian Journal of Rhinology</i> , 2017, 7, 103-107.	0.1	0
502	Diffuse Large B-Cell Lymphomas in Older Adults. , 2018, , 1-31.		0
503	Diffuse Large B-Cell Lymphoma. , 2018, , 770-775.		0
504	Thymic Tumors and Lymphomas: The Clinical Impact of Their Underlying Molecular Features. <i>Current Clinical Pathology</i> , 2018, , 129-161.	0.0	0
506	Aggressive Lymphoma. , 2019, , 387-399.		0
507	Epidemiology, pathogenesis, molecular characteristics, classification and prognosis of the diffuse large B-cell lymphoma. <i>Family Medicine</i> , 2018, , 36-40.	0.1	2
508	Aggressive Lymphoma in Children and Adolescents. <i>Mechanical Engineering Series</i> , 2019, , 245-282.	0.1	0
509	The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. <i>Journal of Cancer Therapy</i> , 2019, 10, 53-68.	0.1	0
510	Immunophenotypic characteristics of diffuse large b-cell lymphoma and expression of C-MYC protein: single Ecuadorian center experience. <i>Revista Colombiana De Cancerología</i> , 2019, 23, 41-44.	0.0	0
512	Malignant Lymphomas. <i>Essentials of Diagnostic Pathology</i> , 2020, , 131-233.	0.0	0
514	TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021063.	0.5	1
515	Cost Analysis of R-CHOP versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. <i>Clinical Hematology International</i> , 2020, 2, 117.	0.7	2
516	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
518	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. <i>Treatment Strategies Hematology</i> , 2012, 2, 68-73.	0.0	2
519	Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 275-86.	0.5	4
520	Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7594-9.	0.5	4
522	Prognostic significance of immunohistochemical subtypes based on the stage of B-cell differentiation in primary CNS lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 1457-1467.	0.5	1

#	ARTICLE	IF	CITATIONS
523	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in <i>IRF4</i> rearrangements. <i>Blood Advances</i> , 2022, 6, 2361-2372.	2.5	26
524	Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma. <i>Current Oncology</i> , 2021, 28, 4821-4831.	0.9	2
525	Hardbound indurated plaque and nodules with <i>œm band</i> A report of secondary cutaneous diffuse large b-cell lymphoma. <i>Indian Journal of Paediatric Dermatology</i> , 2022, 23, 90.	0.0	0
526	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338.	1.7	2
527	Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice. <i>Current Oncology Reports</i> , 2022, 24, 13-21.	1.8	15
528	Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 1313-1327.	2.6	4
529	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls. <i>Current Oncology</i> , 2022, 29, 956-968.	0.9	3
530	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel. <i>Cancers</i> , 2021, 13, 6384.	1.7	24
531	Primary Gastrointestinal Lymphoma. , 0, , .		1
532	Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas. <i>Hemato</i> , 2022, 3, 174-187.	0.2	0
533	The role of cytokeratin 7/20 coordination revisited Machine learning identifies improved interpretative algorithms for cell block immunohistochemistry in aspirates of metastatic carcinoma. <i>Cancer Cytopathology</i> , 2022, 130, 455-468.	1.4	11
534	DLBCL 1L What to Expect beyond R-CHOP?. <i>Cancers</i> , 2022, 14, 1453.	1.7	7
536	WHO classification of lymphomas. , 0, , 228-256.		0
541	Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy. <i>Journal of the College of Physicians and Surgeons-Pakistan: JCPSP</i> , 2014, 24, 722-7.	0.2	0
542	Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment. <i>Diagnostics</i> , 2022, 12, 1087.	1.3	3
543	Basic immunohistochemistry for lymphoma diagnosis. <i>Blood Research</i> , 2022, 57, S55-S61.	0.5	9
544	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. <i>EJHaem</i> , 2022, 3, 722-733.	0.4	1
545	Transient regression and fluctuation of bilateral adrenal masses: a rare presentation of primary adrenal lymphoma. <i>International Surgery Journal</i> , 2022, 9, 1246.	0.0	0

#	ARTICLE	IF	CITATIONS
546	Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2022, 17, e0269570.	1.1	2
547	The Era of Genomic Research for Lymphoma: Looking Back and Forward. <i>Hemato</i> , 2022, 3, 485-507.	0.2	0
548	Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group. <i>Cancer Genetics</i> , 2022, 268-269, 1-21.	0.2	0
549	Diffuse Large B-Cell Lymphomas: From Morphology to Genomic Profiling. , 0, , .		0
550	A Multicenter Study of Clinicopathology and Immunohistochemical Distinction between Adult and Pediatric Large B-Cell Lymphoma. <i>Fetal and Pediatric Pathology</i> , 0, , 1-12.	0.4	1
551	Practical approach to gastrointestinal system lymphoproliferative lesions. <i>Arsiv Kaynak Tarama Dergisi</i> , 2022, 31, 213-230.	0.1	0
552	High-grade B-cell lymphoma. <i>Medicinski Pregled</i> , 2022, 75, 88-95.	0.1	0
553	Lymphoid and Hematopoietic Tumors of the Breast. , 2022, , 805-824.		0
554	Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 179-192.	1.4	9
555	Sequencing therapy in relapsed DLBCL. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 146-154.	0.9	8
557	Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma. <i>Cells</i> , 2023, 12, 196.	1.8	0
558	Identification of MYC/BCL2 Double-expressers Lymphomas in Diffuse Large B Cell Lymphoma Patients and Association with their Prognostic Parameters and Survival Rates: A Single Centre Experience. , 2022, 18, 87-92.		0
559	In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines. <i>Cells</i> , 2023, 12, 596.	1.8	0
560	Epsteinâ€Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Life</i> , 2023, 13, 521.	1.1	4
561	MUM-1 in canine lymphoma: A pilot study. <i>Veterinary Pathology</i> , 2023, 60, 316-319.	0.8	2
562	Ocular and Adnexal Lymphoma: Pathogenesis and Pathology. <i>Essentials in Ophthalmology</i> , 2023, , 15-22.	0.0	0
563	DLBCL Subtypes and Prognosis Based on Immunophenotyping. , 0, , .		0